AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Orthocell (ASX:OCC) Expands into US Market with First Remplir™ | All Ordinaries
July 10, 2025 04:45 PM AEST| By Team Kalkine MediaHighlights,Orthocell secures initial revenue from Remplir™ following regulatory clearance in the US,First surgical procedures performed in Ohio and Florida via ambulatory surgery centres,Company advances logistics and commercial scaling with support...
ASX 300 Penny Stock Radar: Clarity Pharmaceuticals Gains Spotlight
July 10, 2025 04:35 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals maintains development focus in radiopharmaceuticals,Commercial manufacturing agreement in the US strengthens future production plans,ASX 300 company continues clinical trial momentum with multiple programs underway,...
Race Oncology Expands Global Clinical Reach with RC220 Trial Progress
July 10, 2025 03:56 PM AEST| By Team Kalkine MediaHighlights,RC220 Phase 1 trial approved at two Hong Kong hospitals,Expansion supports faster recruitment and regional relevance,Broadening cardio-oncology footprint with international sites,Race Oncology (ASX:RAC) has announced key regulatory progres...
Orthocell (ASX:OCC) Gains Momentum in the US Market | Allords Biotech Update
July 10, 2025 03:37 PM AEST| By Team Kalkine MediaHighlights,Orthocell (OCC) marks first US revenue milestone,FDA-cleared Remplir device used in US surgical procedures,Commercial progress reported following regulatory approval,The global biotech landscape is always evolving, and for Orthocell (ASX:O...
ASX 100 Healthcare Stock ResMed (ASX:RMD) Eyes Growth Through Innovation and Global Reach
July 10, 2025 03:28 PM AEST| By Team Kalkine MediaHighlights,ResMed (RMD) operates in over 140 countries,Focuses on CPAP therapy and SaaS for out-of-hospital care,Listed on both NYSE and ASX, with US reporting standards,ResMed (ASX:RMD), a global player in the medical equipment and digital health sp...
Orthocell (ASX:OCC) Enters US Market with Remplir™: A New Chapter for Nerve Repair and ASX 200 Share Price Watch
July 10, 2025 10:42 AM AEST| By Team Kalkine MediaHighlights,Orthocell,records first US revenue for,Remplir,™,Surgeries in Ohio and Florida mark commercial entry,Positioned for broader rollout in 2025,Orthocell (ASX:OCC), a regenerative medicine company, has officially marked its entry into the US m...
Biome Australia's Record-Breaking FY25: Revenue Surges Amid Growing Demand
July 09, 2025 05:16 PM AEST| By Team Kalkine MediaHighlights,Biome Australia reports record FY25 revenue milestone,Quarterly and monthly sales performance at all-time highs,Strong momentum driven by consistent demand for health products,Biome Australia (ASX:BIO) has released a notable update to the...
Island Pharmaceuticals Fast-Tracks Galidesivir Acquisition to Advance Anti-Viral Pipeline
July 09, 2025 04:40 PM AEST| By Team Kalkine MediaHighlights,Island Pharmaceuticals accelerates galidesivir program acquisition,Strategic focus on Marburg virus treatment development,Priority review voucher offers future regulatory advantage,Island Pharmaceuticals (ASX:ILA),has announced the acceler...
Summerset Group (ASX:SNZ) Supports Rebound in ASX 200 Healthcare Sector
July 09, 2025 04:37 PM AEST| By Team Kalkine MediaHighlights,Summerset Group posts record-breaking Q2 growth,Housing recovery and strong offerings drive sustained momentum,Sector sentiment lifted as ASX 200 shows signs of revival,Summerset Group Holdings Ltd (ASX:SNZ), a dual-listed retirement villa...
Prescient Therapeutics Advances PTX-100 to Phase 2 in Fight Against T-Cell Lymphoma
July 09, 2025 02:45 PM AEST| By Team Kalkine MediaHighlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma,Analysts lift valuation outlook on clinical potential and market size,Prescient expands pipeline with innovative CAR-T platforms,Prescient Therapeutics (ASX...
PTX-100 Phase 2 Trial Advances Prescient Therapeutics (ASX:PTX) in All Ordinaries Spotlight
July 09, 2025 02:27 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics initiates Phase 2 trial for PTX-100 targeting T-Cell Lymphoma,PTX-100 shows activity in patients with limited treatment options,CAR-T platforms CellPryme and OmniCAR add to company’s oncology portfolio,Prescient Ther...
Orthocell's Record-Breaking FY2025 Signals Bold Momentum Beyond Borders
July 09, 2025 01:53 PM AEST| By Team Kalkine MediaHighlights,Orthocell hits record FY2025 revenue milestone,Expansion into the US gains significant traction,Strategic international regulatory approvals fuel growth,Orthocell (ASX:OCC) has delivered an impressive financial performance for FY2025, achi...
Proteomics International (ASX:PIQ) Shows Signs of Recovery After Challenging Year
July 09, 2025 10:03 AM AEST| By Team Kalkine MediaHighlights,Weekly rebound sparks interest in PIQ,Long-term holders still face deep losses,Revenue growth continues despite setbacks,Proteomics International Laboratories (ASX:PIQ) experienced a notable lift in its share price over the past week, brin...
Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues
July 08, 2025 06:25 PM AEST| By Team Kalkine MediaHighlights,Nova Eye Medical reports record FY25 revenue performance,Significant uplift in US market sales drives growth,H2FY25 shows strong momentum across operations,Nova Eye Medical (ASX:EYE) has released its full-year financial results for FY25, s...
Cannabinoid Therapy Steps Up in Slovenia: Argent BioPharma (ASX:RGT) Expands Epilepsy Treatment Reach
July 08, 2025 06:15 PM AEST| By Team Kalkine MediaHighlights,Argent BioPharma expands cannabinoid epilepsy treatment in Slovenia,Successful pilot leads to routine hospital use,Multi-year regulatory collaboration drives clinical adoption,Argent BioPharma (ASX:RGT) has taken a significant step forward...
Sofdra™ Gains Traction: Botanix Pharmaceuticals (ASX:BOT) Reports Positive Growth Momentum
July 08, 2025 05:53 PM AEST| By Team Kalkine MediaHighlights,Sofdra™ shows steady monthly growth post-launch,Over 16,000 prescriptions filled since February,Expansion into new sales territories underway,Botanix Pharmaceuticals (ASX:BOT) has unveiled strong early-stage performance metrics for its der...
PME’s Growth Momentum: Key Insights into This ASX 100 Radiology Software Leader
July 08, 2025 05:43 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus demonstrates robust profit and revenue growth,Strong balance sheet supports operational resilience,Return on equity reflects high capital efficiency,Pro Medicus (ASX:PME), a prominent medical imaging software provider, has made...
Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback
July 08, 2025 04:49 PM AEST| By Team Kalkine MediaHighlights,Monash IVF (MVF) under focus after operational mishap,Adjusted financial outlook reflects anticipated market share shifts,Sector valuation hints at consolidation prospects,Monash IVF (ASX:MVF), a prominent name in Australia’s fertility ser...
CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index
July 07, 2025 06:29 PM AEST| By Team Kalkine MediaHighlights,CSL operates across plasma, flu vaccine, and renal care segments,Part of the ASX 300 Index, reflecting its position among Australia’s largest listed entities,Healthcare demand continues to show global momentum,CSL Ltd (ASX:CSL) remains a p...
Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch
July 07, 2025 04:46 PM AEST| By Team Kalkine MediaHighlights,Nanosonics unveils trophon3 with faster disinfection and digital integration,trophon2 Plus software upgrade brings advanced features to existing systems,Launch extends across multiple regions; FDA review in progress,Nanosonics (ASX:NAN), a...
Advertise your brand on Kalkine Media